Aprogen Biologics Inc. (KRX:003060)
1,738.00
-62.00 (-3.44%)
Sep 1, 2026, 3:30 PM KST
Aprogen Biologics Revenue
Aprogen Biologics had revenue of 23.08B KRW in the quarter ending June 30, 2026, with 54.93% growth. This brings the company's revenue in the last twelve months to 86.18B, up 26.13% year-over-year. In the year 2025, Aprogen Biologics had annual revenue of 73.23B with 8.68% growth.
Revenue (ttm)
86.18B
Revenue Growth
+26.13%
P/S Ratio
0.49
Revenue / Employee
227.39M
Employees
379
Market Cap
42.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.23B | 5.85B | 8.68% |
| Dec 31, 2024 | 67.38B | -19.99B | -22.88% |
| Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
| Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
| Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 630.89B |
| Ildong Holdings | 607.65B |
| HANDOK | 560.89B |
| HLB Pharmaceutical | 251.95B |
| MYUNGMOON Pharm co.,Ltd | 199.82B |
| Kukje Pharma | 181.27B |
| CKD Bio | 159.93B |
| Yuyu Pharma | 144.37B |